Celldex Therapeutics to Present Antibody-Drug Conjugate CDX-014 Preclinical Proof of Concept Data at AACR 2014
Poster details: Abstract # 2649 entitled "Development of an Antibody-drug Conjugate Targeting TIM-1 for the Treatment of Ovarian and Renal Cell Carcinoma" will be presented on
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Sarah CavanaughVice President of Investor Relations & Corporate Communications Celldex Therapeutics, Inc.(781) 433-3161 email@example.com
News Provided by Acquire Media